BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
1063 results:

  • 1. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
    Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and pd-l1.
    Li J; Xu X; Xu K; Zhou X; Wu K; Yao Y; Liu Z; Chen C; Wang L; Sun Z; Jiao D; Han X
    J Exp Clin Cancer Res; 2024 Apr; 43(1):119. PubMed ID: 38641828
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and pd-l1 enhances antitumor responses.
    Tapia-Galisteo A; Sánchez-Rodríguez I; Narbona J; Iglesias-Hernández P; Aragón-García S; Jiménez-Reinoso A; Compte M; Khan S; Tsuda T; Chames P; Lacadena J; Álvarez-Vallina L; Sanz L
    Oncoimmunology; 2024; 13(1):2338558. PubMed ID: 38623463
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The Tumor Microenvironment Mediates the HIF-1α/pd-l1 Pathway to Promote Immune Escape in colorectal cancer.
    Sun J; Zhao Z; Lu J; An W; Zhang Y; Li W; Yang L
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612546
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. [Expression of immune checkpoints pd-l1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].
    Naumov SS; Krakhmal NV; Tashireva LA; Vtorushin SV
    Arkh Patol; 2024; 86(2):6-13. PubMed ID: 38591901
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Case report: Envafolimab causes local skin necrosis.
    Liu JJ; Xu XY; Han H; Wang T; Zhang W; Cui J; Semenov M
    Front Immunol; 2024; 15():1336311. PubMed ID: 38585260
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Deubiquitinase USP4 suppresses antitumor immunity by inhibiting IRF3 activation and tumor cell-intrinsic interferon response in colorectal cancer.
    Zhou Y; Li H; Zhang Y; Zhao E; Huang C; Pan X; Shu F; Liu Z; Tang N; Li F; Liao W
    Cancer Lett; 2024 May; 589():216836. PubMed ID: 38556105
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Potential value of expression of receptor accessory protein 4 for evaluating the prognosis of lower-grade glioma patients.
    Luo S; Liu Z; Chang H; Cheng X; Qian R; Gao Y; Hou C
    Aging (Albany NY); 2024 Mar; 16(7):6188-6211. PubMed ID: 38552216
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
    Kim S; Ghiringhelli F; de la Fouchardière C; Evesque L; Smith D; Badet N; Samalin E; Lopez-Trabada Ataz D; Parzy A; Desramé J; Baba Hamed N; Buecher B; Tougeron D; Bouché O; Dahan L; Chibaudel B; El Hajbi F; Mineur L; Dubreuil O; Ben Abdelghani M; Pecout S; Bibeau F; Herfs M; Garcia ML; Meurisse A; Vernerey D; Taïeb J; Borg C
    Lancet Oncol; 2024 Apr; 25(4):518-528. PubMed ID: 38547895
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Associations of PD-1 and pd-l1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
    Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
    Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic colorectal cancer.
    Gherman A; Bolundut D; Ecea R; Balacescu L; Curcean S; Dina C; Balacescu O; Cainap C
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541123
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Exploring the clinical significance of IL-38 correlation with PD-1, CTLA-4, and FOXP3 in colorectal cancer draining lymph nodes.
    Yuan L; Tan Z; Huang J; Chen F; Hambly BD; Bao S; Tao K
    Front Immunol; 2024; 15():1384548. PubMed ID: 38533512
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer.
    Zhang D; Xie J; Sun F; Xu R; Liu W; Xu J; Huang X; Zhang G
    Cancer Lett; 2024 May; 589():216819. PubMed ID: 38522775
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
    Levy A; Morel D; Texier M; Sun R; Durand-Labrunie J; Rodriguez-Ruiz ME; Racadot S; Supiot S; Magné N; Cyrille S; Louvel G; Massard C; Verlingue L; Bouquet F; Bustillos A; Bouarroudj L; Quevrin C; Clémenson C; Mondini M; Meziani L; Tselikas L; Bahleda R; Hollebecque A; Deutsch E
    Mol Cancer; 2024 Mar; 23(1):61. PubMed ID: 38519913
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Co-inhibition of TGF-β and pd-l1 pathways in a metastatic colorectal cancer mouse model triggers interferon responses, innate cells and T cells, alongside metabolic changes and tumor resistance.
    Nair R; Lannagan TRM; Jackstadt R; Andrusaite A; Cole J; Boyne C; Nibbs RJB; Sansom OJ; Milling S
    Oncoimmunology; 2024; 13(1):2330194. PubMed ID: 38516270
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Serum iron element: A novel biomarker for predicting PD-1 immunotherapy efficacy.
    Luan F; Wang J; Liu L; Liu B; Li F; Zhao J; Lai J; Jiang F; Xu W; Zhang Z; Ran P; Shu Y; Yang Z; Fu G
    Int Immunopharmacol; 2024 Apr; 131():111823. PubMed ID: 38508094
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
    Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
    J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).
    Kim JW; Lee HJ; Lee JY; Park SR; Kim YJ; Hwang IG; Kyun Bae W; Byun JH; Kim JS; Kang EJ; Lee J; Shin SJ; Chang WJ; Kim EO; Sa JK; Park KH
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485184
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. A comprehensive multi-omics analysis identifies a robust scoring system for cancer-associated fibroblasts and intervention targets in colorectal cancer.
    Wang F; Li Z; Xu T; Zhang Q; Ma T; Li S; Wang X
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):124. PubMed ID: 38478111
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Intratumoral injection of interferon gamma promotes the efficacy of anti-PD1 treatment in colorectal cancer.
    Tang Y; Wei J; Ge X; Yu C; Lu W; Qian Y; Yang H; Fu D; Fang Y; Zhou X; Wang Z; Xiao Q; Ding K
    Cancer Lett; 2024 Apr; 588():216798. PubMed ID: 38467181
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 54.